Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse

Documenti analoghi

• Targets for AD treatment: conflicting messages from γ-secretase inhibitors
  di: Sambamurti, Kumar, et al.
  Pubblicazione: (2011)
• Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model
  di: Chen, Xu‐Qiao, et al.
  Pubblicazione: (2020)
• Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N(1)-norPosiphen, (+)-N(8)-norPosiphen and (+)-N(1), N(8)-bisnorPosiphen, their inhibition of amyloid precursor protein, α-synuclein synthesis, interleukin-1β, and cholinergic action
  di: Yu, Qian-sheng, et al.
  Pubblicazione: (2013)
• Leucine Carboxyl Methyltransferase 1 Overexpression Protects Against Cognitive and Electrophysiological Impairments in Tg2576 APP Transgenic Mice
  di: Gnanaprakash, Madhumathi, et al.
  Pubblicazione: (2021)
• Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?
  di: Teich, Andrew F., et al.
  Pubblicazione: (2012)